WO2003044054A3 - Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases - Google Patents

Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases Download PDF

Info

Publication number
WO2003044054A3
WO2003044054A3 PCT/EP2002/012955 EP0212955W WO03044054A3 WO 2003044054 A3 WO2003044054 A3 WO 2003044054A3 EP 0212955 W EP0212955 W EP 0212955W WO 03044054 A3 WO03044054 A3 WO 03044054A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
diseases
autoantibodies
histone
autoimmun
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/012955
Other languages
French (fr)
Other versions
WO2003044054A2 (en
Inventor
Michael Zeppezauer
Arno Schoenberger
Ladislav Cebecauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symbiotec GmbH Gesellschaft zur Forschung und Entwicklung der Biotechnologie
Original Assignee
Symbiotec GmbH Gesellschaft zur Forschung und Entwicklung der Biotechnologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symbiotec GmbH Gesellschaft zur Forschung und Entwicklung der Biotechnologie filed Critical Symbiotec GmbH Gesellschaft zur Forschung und Entwicklung der Biotechnologie
Priority to EP02799722A priority Critical patent/EP1451220A2/en
Priority to AU2002364757A priority patent/AU2002364757A1/en
Publication of WO2003044054A2 publication Critical patent/WO2003044054A2/en
Publication of WO2003044054A3 publication Critical patent/WO2003044054A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Peptides are proposed with antigenic or immunogenic determinants, which result from autoantibodies in the body fluids of patients, who are suffering from autoimmun diseases, in particular diseases of the rheumatic group as systemic lupus erythematosus (SLE), rheumatoid arthritis or systemic sclerosis. In the case of the peptides it is preferably a question of the C terminus of bovine histone H1 with the sequence section 187-211 or corresponding human histon-H1-peptides of the sub-types H1.1, H1.2, H1.3, H1.4, H1.5 and H1.a and the N termini of histone H2B with the sequence section 1-35 and 36-76, which are capable of cross reactions with the autoantibodies (anti-histone-antibodies). The invention furthermore provides ways of forming monoclonal antibodies and antiidiotypical antibodies, which are directed against autoantibodies. The diagnosis of autoimmun peptides and diseases is possible in accordance with the invention with a high degree of certainty and the monoclonal antibodies directed against the autoantibodies are suitable for the production of medicaments for the therapy of said diseases.
PCT/EP2002/012955 2001-11-19 2002-11-19 Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases Ceased WO2003044054A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02799722A EP1451220A2 (en) 2001-11-19 2002-11-19 Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases
AU2002364757A AU2002364757A1 (en) 2001-11-19 2002-11-19 Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/988,165 2001-11-19
US09/988,165 US20030144473A1 (en) 1992-09-16 2001-11-19 Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases

Publications (2)

Publication Number Publication Date
WO2003044054A2 WO2003044054A2 (en) 2003-05-30
WO2003044054A3 true WO2003044054A3 (en) 2004-03-04

Family

ID=25533904

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/012955 Ceased WO2003044054A2 (en) 2001-11-19 2002-11-19 Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases

Country Status (4)

Country Link
US (1) US20030144473A1 (en)
EP (1) EP1451220A2 (en)
AU (1) AU2002364757A1 (en)
WO (1) WO2003044054A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2402368A1 (en) 2010-07-02 2012-01-04 Toscana Biomarkers S.r.l. Histone citrullinated peptides and uses thereof
EP2527841A1 (en) 2011-05-25 2012-11-28 Toscana Biomarkers S.r.l. Methods for the diagnosis of rheumatoid arthritis
US11480568B2 (en) * 2017-09-28 2022-10-25 Yeda Research And Development Co. Ltd. Diagnosis of autoimmune diseases
CN112390855B (en) * 2019-07-31 2022-04-29 上海交通大学医学院附属仁济医院 Application of Pretide-146a in the preparation of medicines for relieving or treating autoimmune diseases
CN110988362B (en) * 2019-12-20 2023-11-14 迈克生物股份有限公司 Anti-histone antibody determination reagents, kits and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0532979A2 (en) * 1991-09-16 1993-03-24 SYMBIOTEC Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie GmbH Peptides for the preparation of means for diagnosis and therapy of systemic lupus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2741653A (en) * 1954-03-19 1956-04-10 Univ California Method of isolating nucleoproteins
US3065141A (en) * 1960-08-24 1962-11-20 Albert E Gessler Separation of nucleoproteins and nucleic acids from aqueous protein mixtures
US4536479A (en) * 1983-03-22 1985-08-20 E. I. Du Pont De Nemours And Company Use of anti-idiotype antibodies in immunoassays
US4818763A (en) * 1984-01-12 1989-04-04 Volker Rusch Biologically active substance with hormonal properties, production process thereof and utilization of histones for medical purposes
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US4701442A (en) * 1985-06-13 1987-10-20 Elena Avram Treatment of symptoms of neoplastic diseases with nucleoproteins
US5034316A (en) * 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0532979A2 (en) * 1991-09-16 1993-03-24 SYMBIOTEC Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie GmbH Peptides for the preparation of means for diagnosis and therapy of systemic lupus

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE GENESEQ [online] 13 June 2000 (2000-06-13), "Human histone H1 isoform H1S-3", XP002249108, Database accession no. AAY57331 *
DATABASE SWALL [online] 1 August 1990 (1990-08-01), "Histone H1.2", XP002249104, Database accession no. P16403 *
DATABASE SWALL [online] 1 August 1990 (1990-08-01), "Histone H1.3", XP002249105, Database accession no. P16402 *
DATABASE SWALL [online] 1 August 1990 (1990-08-01), "Histone H1.5", XP002249107, Database accession no. P16401 *
DATABASE SWALL [online] 1 March 1989 (1989-03-01), "Histone H1.4", XP002249106, Database accession no. P10412 *
DATABASE SWALL [online] 16 October 2001 (2001-10-16), "Histone H1.1", XP002249103, Database accession no. Q02539 *

Also Published As

Publication number Publication date
US20030144473A1 (en) 2003-07-31
AU2002364757A8 (en) 2003-06-10
WO2003044054A2 (en) 2003-05-30
EP1451220A2 (en) 2004-09-01
AU2002364757A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
HK1049279A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases comprising all-d peptides
WO2002096937A3 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
EP1067182A8 (en) Secretory protein or membrane protein
EP1712628A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
NZ332311A (en) Use of autoantigen HC gp-39 and proteins structurally related thereto in immunotherapy of autoimmune diseases particularly rheumatoid arthritis
WO2001046222A3 (en) Peptides designed for the diagnosis and treatment of rheumatoid arthritis
IL135687A0 (en) A novel human checkpoint kinase, hcds1, compositions and methods
CA2078373A1 (en) Peptides for the production of preparations for the diagnosis and therapy of systemic lupus
WO2003044054A3 (en) Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases
WO1998059040A3 (en) Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
WO2002008273A3 (en) 47508, a novel human histone deacetylase family member and uses thereof
WO2001096392A3 (en) 22109, a novel human thioredoxin family member and uses thereof
ZA983488B (en) Isolated nucleic acid molecule coding for tumor rejection antigen precursors mage-c1 and mage-c2 and uses thereof
WO2002044202A3 (en) Mutated immunogenic peptides derived from r9m, polynucleotides coding for same and therapeutic uses thereof
WO1997046253A3 (en) Immunotherapy for autoimmune disease
ZA961628B (en) Diagnostic method test kit drug and therapeutic treatment for autoimmune diseases
EP0723014A3 (en) cDNA of DOCK180 gene and DOCK180 protein
CA2436779A1 (en) Human mitochondrial proteins and polynucleotides encoding the proteins
WO2001090321A3 (en) 55158, a novel human carbonic anhydrase and uses thereof
WO2002016568A3 (en) 46863, a human methyltransferase and uses thereof
WO2002094184A3 (en) Vaccines for the treatment of autoimmune disease
WO2002016592A3 (en) Atcr-1, a human acyltransferase and uses thereof
WO2003048188A3 (en) 15603, a human ion channel family member
WO2002026804A3 (en) 84241, a human ring finger family member and uses thereof
WO2002040674A3 (en) '67118', '67067' and '62092', human proteins and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002799722

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002799722

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP